SDGR

Schrödinger, Inc. [SDGR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SDGR Stock Summary

Top 10 Correlated ETFs

SDGR

Top 10 Correlated Stocks

SDGR

In the News

SDGR Financial details

Company Rating
-
Market Cap
1.91B
Income
40.72M
Revenue
216.67M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
867
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
49.39
Forward P/E
-
PEG
-3.87
P/S
10.96
P/B
3.87
P/C
-
P/FCF
-15.99
Quick Ratio
5.03
Current Ratio
5.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-127.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
20.43%
Revenue Q/Q
74.13%
EPS Q/Q
-50%
-
-
-
-
SMA20
9.09%
SMA50
-
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
-0.26%
Gross Margin
61%
Oper. Margin
-88%
Profit Margin
22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.76-59.24
52W High
-80.27%
52W Low
-41.8%
RSI
47
Rel Volume
0.96
Avg Volume
888.46K
Volume
852.24K
Perf Week
2.02%
Perf Month
-3.16%
Perf Quarter
-34.53%
Perf Half Y
-48.31%
-
-
-
-
Beta
1.566
-
-
Volatility
0.22%, 0.45%
Prev Close
-4.9%
Price
11.64
Change
0.61%

Something similar

Top by Market Cap
GOOGL
MSFT
LLY.SW
TSLA
VOO
Top Correlated ETFs
EKG
XSW
HERO.TO
IFED
OGIG
Top Correlated Stocks
OWLT
ALRM
UBER
AMTD
MITK
Similar Market Cap
BOY.L
BB
WTAN.L
SHOO
TCNNF

Company Profile

Healthcare Medical - Healthcare Information Services
  • Volume Average 888.46K
  • Market Capitalization 1.91B
  • Employee 867
  • CEO Dr. Ramy Farid Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 2020-02-06
  • Website https://www.schrodinger.com

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.